Lundbeck to acquire Ovation Pharmaceuticals
H Lundbeck and Ovation Pharmaceuticals Inc today announced that they have entered into a definitive transaction agreement under which Lundbeck, through the wholly owned subsidiary Lundbeck Inc, will acquire Ovation in an all cash transaction valuing Ovation at up to $900 million or approximately DKK 5.2 billion.
Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.